Seres Therapeutics

Seres Therapeutics is a biotechnology company pioneering the development of microbiome therapeutics to treat serious diseases. Founded in 2010 and based in Cambridge, Massachusetts, the company focuses on leveraging the human microbiome—the trillions of microorganisms in the body—to create novel treatments. Its lead program targets recurrent *Clostridioides difficile* infection, representing a significant advance in the field. The company's work is built upon foundational research from institutions like the Massachusetts Institute of Technology and the Broad Institute.

History

The company was co-founded in 2010 by a group of scientists and entrepreneurs, including David A. Berry and John G. Aunins, with early intellectual property stemming from research conducted at the Massachusetts Institute of Technology and the Harvard-affiliated Broad Institute. Initial financing was secured from prominent venture capital firms such as Flagship Pioneering, which has incubated numerous life sciences companies. In 2015, it completed an initial public offering on the NASDAQ under the ticker symbol "MCRB", raising capital to advance its clinical programs. A landmark event occurred in 2022 when the U.S. Food and Drug Administration accepted its Biologics License Application for its lead candidate, marking a pivotal moment for the entire microbiome therapeutics sector.

Technology and platform

The core technology is based on the ecological restoration of a healthy microbiome using consortia of live bacteria. This approach, often termed microbiome restoration therapy, involves identifying key bacterial taxa that are depleted in specific disease states. The company utilizes advanced methods like 16S ribosomal RNA sequencing and metagenomics to analyze microbial communities from healthy donors and patients. Its manufacturing process, developed in collaboration with contract organizations like Bushu Pharmaceuticals, is designed to produce standardized, orally administered bacterial spores. This platform is being applied across multiple therapeutic areas, including infectious disease, oncology, and immunology.

Clinical development and pipeline

The most advanced investigational product, SER-109, is a microbiome therapeutic for preventing recurrent *Clostridioides difficile* infection. Its development included the landmark ECOSPOR III clinical trial, which demonstrated significant efficacy. The company is also developing SER-155, a consortium aimed at preventing infections and graft-versus-host disease in immunocompromised patients, such as those undergoing allogeneic hematopoietic stem cell transplantation. Earlier-stage pipeline candidates target conditions like ulcerative colitis and are being explored in combination with immune checkpoint inhibitors like Keytruda for oncology applications. Clinical trials are conducted in partnership with leading academic medical centers including the Memorial Sloan Kettering Cancer Center.

Collaborations and partnerships

A major strategic collaboration was established with the Swiss pharmaceutical giant Nestlé Health Science in 2016, which included a significant equity investment and co-development rights for SER-109 in markets outside the United States and Canada. In 2021, the company entered into a license and commercialization agreement with the Japanese pharmaceutical company Aimmune Therapeutics for SER-109. Research collaborations have been formed with prestigious institutions such as the University of Texas MD Anderson Cancer Center to explore microbiome applications in oncology. The company also works with the U.S. Department of Defense on projects related to gastrointestinal health.

Financial performance and business model

The company operates with a hybrid business model that combines internal research and development with strategic partnership funding. Major revenue streams have included upfront payments, milestone fees, and research funding from collaborators like Nestlé Health Science. Like many development-stage biotechnology firms, it has reported net losses as it invests heavily in clinical trials and manufacturing scale-up. Financing activities have included follow-on public offerings and convertible debt issuances. Its financial position and runway are closely tied to the regulatory and commercial progress of its lead asset, SER-109, with potential future revenue from royalties and product sales.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Companies listed on NASDAQ